Oncogene-induced senescence (OIS) is thought to be a barrier to malignant transformation resulting from the strong activation of oncogenes. In this issue of Cancer Cell, Damsky and colleagues suggest activation of mTORC1 and mTORC2 is required for OIS evasion in human melanomas harboring oncogenic BRAF mutations
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces ...
International audienceNormal cells possess a limited proliferative life span, after which they enter...
International audienceNormal cells possess a limited proliferative life span, after which they enter...
Oncogene-induced senescence (OIS) is thought to be a barrier to malignant transformation resulting f...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogene-induced senescence is an important barrier during melanomagenesis. In this issue of Cancer ...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
On acquisition of an oncogenic mutation, primary human and mouse cells can enter oncogene-induced se...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces ...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces ...
International audienceNormal cells possess a limited proliferative life span, after which they enter...
International audienceNormal cells possess a limited proliferative life span, after which they enter...
Oncogene-induced senescence (OIS) is thought to be a barrier to malignant transformation resulting f...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogene-induced senescence is an important barrier during melanomagenesis. In this issue of Cancer ...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
On acquisition of an oncogenic mutation, primary human and mouse cells can enter oncogene-induced se...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces ...
Oncogene-induced senescence (OIS) is a well-documented phenomenon both in vitro and in vivo as a tum...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Oncogenic signaling in melanocytes results in oncogene-induced senescence (OIS), a stable cell-cycle...
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces ...
International audienceNormal cells possess a limited proliferative life span, after which they enter...
International audienceNormal cells possess a limited proliferative life span, after which they enter...